Results 31 to 40 of about 27,341 (230)

Low-density lipoprotein-cholesterol lowering effect of a nutraceutical regimen with or without ezetimibe in hypercholesterolaemic patients with statin intolerance

Frontiers in Cardiovascular Medicine, 2022
BackgroundStatins are the most widely prescribed medication to lower low-density lipoprotein cholesterol (LDL-c). However, a significant portion of patients are unable to tolerate them due to side effects, most commonly muscle related.
Natalie C. Ward, Christopher M. Reid, Gerald F. Watts, Gerald F. Watts   +3 more
doaj   +1 more source

Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights

Drug Design, Development and Therapy, 2022
Cardiovascular disease is one of the leading causes of death around the world with various efforts being made to reduce risk in patients through preventive measures.
Maya R. Chilbert, Dylan C. VanDuyn, S. Salah, C. Clark, Q. Ma   +4 more
semanticscholar   +1 more source

Densitometric Determination of Ezetimibe in the Presence of its Alkaline Degradation Product [PDF]

Journal of Advanced Pharmacy Research, 2018
Objectives: A simple, accurate, selective and sensitive densitometric method was developed for the determination of ezetimibe in the presence of its alkaline degradation product.
khalid Attia, Ashraf Abdelfattah, Nasr Elabasawi, Ahmad Abo-serie, Samir Morshedy   +4 more
doaj   +1 more source

Impact of combination therapy with statin and ezetimibe on secondary prevention for post-acute myocardial infarction patients in the statin era

International Journal of Cardiology: Heart & Vasculature, 2015
Background: Little is known concerning the effect of ezetimibe for secondary prevention in post-myocardial infarction (MI) patients. In this study, we investigated the secondary prevention effect of ezetimibe for post-MI patients.
Soichiro Ebisawa, Atsushi Izawa, Yasushi Ueki, Hirofumi Hioki, Masatoshi Minamisawa, Naoto Hashizume, Naoyuki Abe, Yuichiro Kashima, Takashi Miura, Takahiro Takeuchi, Hirohiko Motoki, Ayako Okada, Yusuke Miyashita, Jun Koyama, Uichi Ikeda   +14 more
doaj   +1 more source

Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol®:an open-label, randomized, two-sequence crossover study in healthy Chinese subjects

BMC Pharmacology and Toxicology, 2023
Background Ezetimibe is a new class of antihyperlipidemic agent indicated for the prevention of atherosclerosis disease and for the treatment of hypercholesterolemia.
Feifei Sun, Yanping Liu, Ting Li, Pingping Lin, Xin Jiang, Xin Li, Chenjing Wang, Xiaomeng Gao, Yaping Ma, Yao Fu, Yu Cao   +10 more
doaj   +1 more source

Orlistat and ezetimibe could differently alleviate the high-fat diet-induced obesity phenotype by modulating the gut microbiota

Frontiers in Microbiology, 2022
This study aimed to evaluate the possible anti-obesity effects of orlistat and ezetimibe and determine the mechanism by which they alter the composition of gut microbiota and short-chain fatty acids (SCFAs) in mice with a high-fat diet (HFD)-induced ...
Jin Jin, Jiani Wang, R. Cheng, Yan Ren, Z. Miao, Yating Luo, Qingqing Zhou, Yigui Xue, Xi Shen, F. He, H. Tian   +10 more
semanticscholar   +1 more source

Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe

Journal of Lipid Research, 2005
Consumption of plant sterols and treatment with ezetimibe both reduce cholesterol absorption in the intestine. However, the mechanism of action differs between the two treatments, and the consequences of combination treatment are unknown.
Lily Jakulj, Mieke D. Trip, Thomas Sudhop, Klaus von Bergmann, John J.P. Kastelein, Maud N. Vissers   +5 more
doaj   +1 more source

Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: A meta-analysis of randomized controlled studies

PLoS ONE, 2022
Statin is highly recommended for dyslipidemia to prevent atherosclerosis-related cardiovascular diseases and death. The aim of this study was to compare the efficacies and safeties of low/moderate-intensity statin plus ezetimibe combination therapy vs ...
Young‐Mi Ah, M. Jeong, H. Choi
semanticscholar   +1 more source

Inhibition of Smooth Muscle Cell Proliferation by Ezetimibe via the Cyclin D1-MAPK Pathway

Journal of Pharmacological Sciences, 2014
.: Proliferation of vascular smooth muscle cells (VSMCs) contributes to the development of atherosclerosis. Ezetimibe is a new lipid lowering agent that inhibits cholesterol absorption.
Li Qin, Yun-Bo Yang, Yi-Xin Yang, Yong-Zhen Gong, Xiao-Ling Li, Gui-Yuan Li, Hong-Dan Luo, Xue-Jiao Xie, Xi-Long Zheng, Duan-Fang Liao   +9 more
doaj   +1 more source

New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia

Current Opinion in Endocrinology, Diabetes & Obesity, 2022
Purpose of review A number of new cholesterol-lowering drugs have been recently developed and approved, enriching the pharmacological armamentarium beyond and above statins.
A. Pirillo, A. Catapano
semanticscholar   +1 more source